REFERENCES
1. Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21(4):517-33.
2. Hong SM, Park CY, Hwang DM, Han KA, Lee CB, Chung CH, et al. Efficacy and safety of adding evogliptin versus sitagliptin for metformin-treated patients with type 2 diabetes: A 24-week randomized, controlled trial with open label extension. Diabetes Obes Metab. 2017;19(5):654-63.
3. Park J, Park SW, Yoon KH, Kim SR, Ahn KJ, Lee JH, et al. Efficacy and safety of evogliptin monotherapy in patients with type 2 diabetes and moderately elevated glycated haemoglobin levels after diet and exercise. Diabetes, Obesity and Metabolism. 2017;19(12):1681-7.
4. Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, et al. Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers. Drug Des Devel Ther. 2014;8:1709-21.
5. Kim HJ, Kwak WY, Min JP, Lee JY, Yoon TH, Kim HD, et al. Discovery of DA-1229: a potent, long acting dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. Bioorganic & medicinal chemistry letters. 2011;21(12):3809-12.
6. Oh E, Choi C, Kim C, Kim K, Kim Y, Kim S, et al. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. Journal of clinical pharmacy and therapeutics. 2017;42(6):689-94.
7. Chan JC, Malik V, Jia W, Kadowaki T, Yajnik CS, Yoon K-H, et al. Diabetes in Asia: epidemiology, risk factors, and pathophysiology. Jama. 2009;301(20):2129-40.
8. Heather D. Langtry, Balfour JA. Glimepiride. Drugs. 1998;55(4):563-87.
9. Hotta N. A new perspective on the biguanide, metformin therapy in type 2 diabetes and lactic acidosis. Journal of diabetes investigation. 2019.
10. Ko S-H, Hur K-Y, Rhee SY, Kim N-H, Moon MK, Park S-O, et al. Antihyperglycemic agent therapy for adult patients with type 2 diabetes mellitus 2017: a position statement of the Korean Diabetes Association. Diabetes & metabolism journal. 2017;41(5):337-48.
11. McGuire H, Longson D, Adler A, Farmer A, Lewin I. Management of type 2 diabetes in adults: summary of updated NICE guidance. Bmj. 2016;353:i1575.
12. Serra D, He Y, Bullock J, Riviere G, Balez S, Schwartz S, et al. Evaluation of pharmacokinetic and pharmacodynamic interaction between the dipeptidyl peptidase IV inhibitor vildagliptin, glyburide and pioglitazone in patients with Type 2 diabetes. International journal of clinical pharmacology and therapeutics. 2008;46(7):349-64.
13. Friedrich C, Metzmann K, Rose P, Mattheus M, Pinnetti S, Woerle HJ. A randomized, open-label, crossover study to evaluate the pharmacokinetics of empagliflozin and linagliptin after coadministration in healthy male volunteers. Clinical therapeutics. 2013;35(1):A33-A42.
14. Niemi M, Backman JT, Neuvonen M, Laitila J, Neuvonen PJ, Kivistö KT. Effects of fluconazole and fluvoxamine on the pharmacokinetics and pharmacodynamics of glimepiride. Clinical Pharmacology & Therapeutics. 2001;69(4):194-200.
15. Macha S, Mattheus M, Pinnetti S, Seman L, Woerle HJ. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter 2 inhibitor, and glimepiride following co-administration in healthy volunteers: a randomised, open-label, crossover study. Journal of Diabetes Research and Clinical Metabolism. 2012;1(1):14.
16. Tripathi AS, Timiri AK, Mazumder PM, Chandewar A. Does glimepiride alter the pharmacokinetics of sildenafil citrate in diabetic nephropathy animals: investigating mechanism of interaction by molecular modeling studies. Journal of molecular modeling. 2015;21(10):276.
17. Ryan AS, Egan JM, Habener JF, Elahi D. Insulinotropic hormone glucagon-like peptide-1-(7–37) appears not to augment insulin-mediated glucose uptake in young men during euglycemia. The Journal of Clinical Endocrinology & Metabolism. 1998;83(7):2399-404.
18. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. The Journal of clinical investigation. 1993;91(1):301-7.
19. Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. American Journal of Physiology-Endocrinology And Metabolism. 2004;287(2):E199-E206.
20. Jung CH, Park CY, Ahn KJ, Kim NH, Jang HC, Lee MK, et al. A randomized, double-blind, placebo-controlled, phase II clinical trial to investigate the efficacy and safety of oral DA-1229 in patients with type 2 diabetes mellitus who have inadequate glycaemic control with diet and exercise. Diabetes Metab Res Rev. 2015;31(3):295-306.
21. Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, et al. Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects. Drug Des Devel Ther. 2016;10:2525-34.
22. Dunning B, Foley J, Ahrén B. Alpha cell function in health and disease: influence of glucagon-like peptide-1. Diabetologia. 2005;48(9):1700-13.